Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Skin Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Carcinoma 1

Interventions

Specimen Handling 602pembrolizumab 557Magnetic Resonance Spectroscopy 527Carboplatin 422Cyclophosphamide 370Cisplatin 369Biopsy 349Paclitaxel 304Gemcitabine 299Nivolumab 298Radiotherapy 256Bevacizumab 232Dexamethasone 207fludarabine 203Docetaxel 185durvalumab 177atezolizumab 172Oxaliplatin 170Fluorouracil 166venetoclax 164Rituximab 163Pemetrexed 161Doxorubicin 157Radiation 155Capecitabine 155Radiosurgery 145Etoposide 137Leucovorin 133Ipilimumab 132Lenalidomide 129

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × MAPRE1 protein, human × 90 days × Clear all
NCT04349436 2026-04-22

ARTACUS

Replimune, Inc.

Phase 1/2 Active not recruiting
69 enrolled
Dermatologic

Carcinoma, Carcinoma, Basal Cell, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell

NCT06216938 2026-04-13

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

University of Pittsburgh

Phase EARLY_PHASE1 Recruiting
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡